Sort   by:  
 Page size 
MetabolomicsThe Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells
Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribo...
2016-11-07 | MTBLS337 | MetaboLights
ProteomicsProteomic analysis identifies novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
Resistance to Human Epidermal Growth Factor Receptor (HER)-targeted cancer therapies appear to be occurring via common pathways, despite differences in their mechanism of action. This suggests that combination therapies targeting alternative pathways will be needed to overcome resistance. We have us...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-28 | MSV000080706 | MassIVE
UnknownProgress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.
Not available
S-EPMC8735837 | biostudies-literature
UnknownHer-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates.
Not available
S-EPMC9603928 | biostudies-literature
UnknownHER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment.
Not available
S-EPMC9139811 | biostudies-literature
ProteomicsProteomic analysis identifies novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
Resistance to Human Epidermal Growth Factor Receptor (HER)-targeted cancer therapies appear to be occurring via common pathways, despite differences in their mechanism of action. This suggests that combination therapies targeting alternative pathways will be needed to overcome resistance. We have us...
ORGANISM(S): Homo sapiens (Human) 
2016-02-22 | PXD002057 | Pride
Breast cancer Proteomics Emt Her2 Acquired resistance 
TranscriptomicsResistance of primary ovarian cancer cells to oncolytic adenoviruses
This SuperSeries is composed of the following subset Series: GSE15350: Resistance of primary ovarian cancer cells to oncolytic adenoviruses part1 of 2 GSE15351: Resistance of primary ovarian cancer cells to oncolytic adenoviruses part2 of 2 Refer to individual Series
ORGANISM(S): Homo sapiens 
2009-04-01 | E-GEOD-15473 | biostudies-arrayexpress
UnknownMolecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Not available
S-EPMC9302303 | biostudies-literature
TranscriptomicsRNA sequencing of endocrine resistant breast cancer
*** This submission includes RNA data, with DNA files available under a different accession number*** Purpose: Endocrine therapy resistance remains the greatest challenge for treating hormone receptor positive breast cancer patients. We aim to identify molecular mechanisms underlying endocrine ther...
ORGANISM(S): Homo sapiens 
2022-09-01 | E-MTAB-9917 | biostudies-arrayexpress
TranscriptomicsIntegrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Abstract BACKGROUND: The basal-like breast cancer (BLBC) subtype is characterized by positive staining for basal mammary epithelial cytokeratin markers, lack of hormone receptor and HER2 expression, and poor prognosis with currently no approved molecularly-targeted therapies. The oncogenic signaling...
ORGANISM(S): Homo sapiens 
2016-08-21 | E-GEOD-74667 | biostudies-arrayexpress
Sort   by:  
 Page size